s0099994
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.400
- ESTROGEN_RESPONSE_LATE+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
- SPERMATOGENESIS+0.300
- APICAL_SURFACE+0.200
- E2F_TARGETS+0.200
- ESTROGEN_RESPONSE_EARLY+0.200
- KRAS_SIGNALING_DN+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- XENOBIOTIC_METABOLISM+0.200
Top 10 suppressed
- TGF_BETA_SIGNALING-0.400
- UV_RESPONSE_DN-0.400
- KRAS_SIGNALING_UP-0.300
- MYC_TARGETS_V1-0.300
- PROTEIN_SECRETION-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- ALLOGRAFT_REJECTION-0.200
- DNA_REPAIR-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.200
- ANDROGEN_RESPONSE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-NK-A7XE-01A-12R-A405-07 | — | cohortSQ1 | 0.711 |
| 2 | 13e18e29-9f8a-4bd4-9a5d-e6c30668d07a | — | — | 0.661 |
| 3 | TCGA-77-A5GA-01A-11R-A27Q-07 | — | cohortSQ2 | 0.650 |
| 4 | TCGA-33-A5GW-01A-11R-A27Q-07 | — | cohortSQ2 | 0.634 |
| 5 | TCGA-53-A4EZ-01A-12R-A24X-07 | — | cohortA3 | 0.625 |
| 6 | TCGA-39-5027-01A-21R-1820-07 | — | cohortSQ2 | 0.624 |
| 7 | f02aa649-f382-4f91-9a51-ce73199f8fbc | — | — | 0.619 |
| 8 | MNG1267 | — | — | 0.619 |
| 9 | ea9f5a96-93d4-4724-bc4b-2813fa8a35ae | — | — | 0.618 |
| 10 | SRR8943039 | — | — | 0.613 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |